Vir Biotechnology, Inc. (VIR) Shares outstanding analysis
- Shares outstanding · latest quarter: Value 169.22M; Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 1 year ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 5 years ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares change · vs previous quarter: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
Shares outstanding analysis
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Shares outstanding · latest quarter | 169.22M | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 1 year ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 5 years ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
| Shares count change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current quarter shares | 169.22M shares | |
| Previous quarter shares | (m) |
Shares means common shares outstanding, adjusted to the same split basis for comparison. It is a count, not USD or convertible securities; B means billion shares.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current quarter shares (shares) | Shares count change · vs previous quarter | Shares change (%) · vs previous quarter |
|---|---|---|---|
| 2026-06-30 | 169.22M | (m) | (m) |
| 2026-03-31 | 168.65M | (m) | (m) |
| 2025-09-30 | 139.13M | (m) | (m) |
| 2025-06-30 | 138.92M | (m) | (m) |
| 2025-03-31 | 138.24M | (m) | (m) |
| 2024-09-30 | 137.72M | (m) | (m) |
| 2024-06-30 | 136.64M | (m) | (m) |
| 2024-03-31 | 136.06M | (m) | (m) |
| 2023-09-30 | 134.52M | (m) | (m) |
| 2023-06-30 | 134.25M | (m) | (m) |
| 2023-03-31 | 133.98M | (m) | (m) |
| 2022-12-31 | 133.53M | (m) | (m) |
| 2022-09-30 | 133.12M | (m) | (m) |
| 2022-06-30 | 132.64M | (m) | (m) |
| 2022-03-31 | 132.38M | (m) | (m) |
| 2021-12-31 | 132.30M | (m) | (m) |
| 2021-09-30 | 130.88M | (m) | (m) |
| 2021-06-30 | 130.61M | (m) | (m) |
| 2021-03-31 | 130.04M | (m) | (m) |
| 2020-09-30 | 127.39M | (m) | (m) |
| 2020-06-30 | 127.05M | (m) | (m) |
| 2020-03-31 | 117.90M | (m) | (m) |
| 2019-09-30 | 109.68M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |